Health related quality of life outcomes in patients treated for metastatic kidney cancer: A pilot study

Journal of Urology

Volumn 157, Issue 5, 1997, Pages 1608-1612

  Litwin, M S ^a   Fine, J T ^a   Dorey, F ^a   Figlin, R A ^a   Belldegrun, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

kidney neoplasms; neoplasm metastasis; quality of life

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; KIDNEY CANCER; LYMPHOCYTIC INFILTRATION; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM;

EID: 0030892383     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64807-9     Document Type: Article

References (28)

1. Brazier J.E. Harper R. Jones N.M.B. O'Cathain A. Thomas K.J. Usherwood T. Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care Brit. Med. J. 305 1992 160
2. Ganz P.A. Schag C.A.C. Cheng H.L. Assessing the quality of life-a study in newly-diagnosed breast cancer patients J. Clin. Epidemiol. 43 1990 75
3. Coates A. Gebski V. Bishop J.F. Jeal P.N. Woods R.L. Snyder R. Tattersall M.H. Byrne M. Harvey V. Gill G. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies New Engl. J. Med. 317 1987 1490
4. Tannock I.F. Treating the patient, not just the cancer New Engl. J. Med. 317 1987 1534
5. Tannock I.F. Management of breast and prostate cancer: how does quality of life enter the equation? Oncology 4 1990 149
6. Litwin M.S. Measuring health related quality of life in men with prostate cancer J. Urol. 152 1994 1882
7. Quesada J.R. Biologic response modifiers in the therapy of metastatic renal cell carcinoma Sem. Oncol. 15 1988 396
8. de Kernion J.B. Sarna G. Figlin R.A. Lindner A. Smith R.B. The treatment of renal cell carcinoma with human leukocyte alpha-interferon J. Urol. 130 1983 1063
9. Quesada J.R. Swanson D.A. Trindade A. Gutterman J.U. Renal cell carcinoma: antitumor effects of leukocyte interferon Cancer Res. 43 1983 940
10. Rosenberg S.A. Lotze M.T. Yang J.C. Aebersold P.M. Linehan W.M. Seipp C.A. White D.E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients Ann. Surg. 210 1989 474
11. Figlin R.A. Belldegrun A. Moldawer N. Zeffren J. de Kernion J.B. Concomitant administration of recombinant human interleukin-2 and recombinant interferon-alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma J. Clin. Oncol. 10 1992 414
12. Rosenberg S.A. Spiess P. Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 1986 1318
13. Belldegrun A. Pierce W. Kaboo R. Tso C. Shan H. Turcillo P. Moldawer N. Golub S. de Kernion J. Figlin R. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma J. Urol. 150 1993 1384
14. Belldegrun A. Muul L.M. Rosenberg S.A. Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity Cancer Res. 48 1988 206
15. Rosenberg S.A. Packard B.S. Aebersold P.M. Solomon D. Topalian S.L. Toy S.T. Simon P. Lotze M.T. Yang J.C. Seipp C.A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report New Engl. J. Med. 319 1988 1676
16. Pierce W.C. Belldegrun A. Figlin R.A. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma Sem. Oncol. 22 1995 74
17. Patrick D.L. Deyo R.A. Generic and disease-specific measures in assessing health status and quality of life Med. Care 27 suppl. 1989 S217
18. Ware J.E. Sherbourne C.D. The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection Med. Care 30 1992 473
19. Stewart A.L. Greenfield S. Hays R.D. Functional status and well-being of patients with chronic conditions J.A.M.A. 262 1989 907
20. Ware J.E. Snow K.K. Kosinski M. RAND 36-Item Health Survey Health Survey: Manual and Interpretation Guide 1993 Health Institute, New England Medical Center Boston
21. Ganz P.A. Schag C.A.C. Lee J.J. Sim M.S. The CARES: a generic measure of health-related quality of life for patients with cancer Qual. Life Res. 1 1992 19
22. Schag C.A.C. Heinrich R.L. Development of a comprehensive quality of life measurement tool: CARES Oncology 4 1990 135
23. Schag C.A.C. Ganz P.A. Henrich R.L. Cancer Rehabilitation Evaluation System-short form (CARES-SF): a cancer specific rehabilitation and quality of life instrument Cancer 68 1991 1406
24. Schag C.A.C. Heinrich R.L. Cancer Rehabilitation Evaluation System (CARES) Manual 1988 Cares Consultants
25. Greenfield S. Apolone G. McNeil B.J. Cleary P.D. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: Co-morbidity and outcomes after hip replacement Med. Care 31 1993 141
26. Osband M.E. Lavin P.T. Babayan R.K. Graham S. Lamm D.L. Parker B. Sawczuk I. Ross S. Krane R.J. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma Lancet 335 1990 994
27. Moinpour C.M. Feigl P. Metch B. Kayden K.A. Meyskens F.L. Crowley J. Quality of life end points in cancer clinical trials: review and recommendations J. Natl. Cancer Inst. 81 1989 485
28. World Health Organization Constitution of the World Health Organization, Basic Documents 1948 World Health Organization Geneva